Sentiss Pharma Private Limited

Key Metrics of Sentiss Pharma Private Limited

Revenue₹1,424 Cr▲ 15.9% YoYFY 2025-26

EBITDA₹242 Cr▲ 33.1% YoY

Net profit₹160 Cr▲ 346.1% YoY

Net worth—

Competitors10identified

About Sentiss Pharma Private Limited

Sectors

Pharmaceuticals & HealthcareFormulations & Contract Manufacturing

Company details

Registered office: 212 Ashirwad Commercialcomplex D-i Green Park, New Delhi, Delhi -, Delhi, In-dl, 110016

Operational Areas of Sentiss Pharma Private Limited

Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing

Company summary

Entity details

CINU74899DL1994PTC056894

LEI code335800PKYH6NBE2XU717

State codeDL

PIN code110016

Current legal nameSENTISS PHARMA PRIVATE LIMITED

Classification—

Listing statusUnlisted

Registration no.056894

Company age—

PAN—

CountryIndia

CityDelhi

StateDelhi

Current statusActive

Date of incorporation—

Registrar of companies—

Authorised capital—

Paid-up capital—

Employee count—

Compliance

Last AGM date—

Last balance sheet—

Next filing dueMGT-7 for FY 2025-26 · 29 Nov 2026

Industry classification

NIC code74899

Description of main activityOther business activities (consultancy, engineering, advertising, staffing)

Description of business activityOther business activities (consultancy, engineering, advertising, staffing)

SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing

Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Sign in to continue See plans & pricing

Filing compliance

AGM for FY 2025-2630 Sep 2026 Statutory due date passed

AOC-4 for FY 2025-2630 Oct 2026 Statutory due date passed

MGT-7 for FY 2025-2629 Nov 2026 Statutory due date · 25 days left

Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.

Vendor checks & payment capacity

Sign in with access to company financials to review vendor evidence.

Credit ratings

ICRA · 08 Oct 2026 ICRA A+ Stable outlook · Short term A1 · Upgraded

Change in last 12 months—

Change since first rating on record—since Oct 2026

Rating actions11 up · 0 down

Liquidity (ICRA)Adequate

PositiveUpgraded by ICRA on 08 Oct 2026

Rating history

Rating actions

Date	Agency	Action	Long term	Short term	Outlook	Rated amount	Rationale
08 Oct 2026	ICRA	Upgraded	A+	A1	Stable	₹600 Cr	View

Credit strengths (ICRA, Oct 2026)

+ Established position in the Russian ophthalmic drugs industry

SPPL is positioned among the top two companies in the Russian ophthalmic drugs industry with a leading presence in the broader CIS region as well.

+ Healthy financial profile

SPPL has a healthy financial profile characterised by a healthy cashflow from operations, adequate liquidity position and string debt protection metrics.

+ Improving geographical diversification

In June 2023, SPPL acquired a Swiss ophthalmic formulations manufacturing entity— Akorn AG—along with some abbreviated new drug applications (ANDAs) for $36.45 million through insolvency proceedings.

Credit challenges

− High therapeutic concentration

SPPL is focused on the ophthalmic therapy, which exposes the company to risks associated with high therapeutic concentration, including but not limited to event-based risks that can impact the growth rate, sales or the prices of drugs in the ophthalmic industry.

− Exposure to regulatory risks and volatility in forex rates

Similar to its peers, SPPL is exposed to regulatory risks and litigations, including scrutiny by agencies like the USFDA and the Swissmedic.

Could lead to an upgrade

ICRA could upgrade SPPL’s ratings if the company sees strong growth in revenue and profitability, as its US business scales up and supplements the growth, resulting in strengthening of its

Could lead to a downgrade

The ratings can be downgraded in case of a sustained pressure on SPPL’s revenues and earnings and/or a higher-than expected debt-funded capex resulting in deterioration in the credit metrics. A specific metric that could cause a downgrade of SPPL’s ratings is if the total debt/OPBDITA is above 1.5 times on a sustained basis.

Agency-reported financials (ICRA, 08 Oct 2026)

Metric	FY2025	FY2026
Operating income	₹1,229 Cr	₹1,424 Cr
PAT	₹35.80 Cr	₹160 Cr
OPBDIT/OI	14.8%	17.0%
PAT/OI	2.9%	11.2%
Total outside liabilities/Tangible net worth (times)	0.60×	0.60×
Total debt/OPBDIT (times)	1.40×	1.30×
Interest coverage (times)	4.10×	3.90×
Revenue growth (YoY)	—	15.9%
EBITDA (margin × income)	₹182 Cr	₹242 Cr
Implied total debt (debt/EBITDA × EBITDA)	₹255 Cr	₹315 Cr
Implied interest cost (EBITDA ÷ coverage)	₹44.35 Cr	₹62.06 Cr

Borrowings & rated debt

Rated borrowing limits (latest)₹600 Cr

Limits raised0 times1 new facility rated

Facility mix

Rated facilities

Facility	Type	Previous	Current	Change	Rating	Action	Agency
Long-term short-term – Fund-based non fund [ICRA] A ()	Non-fund based limits	—	₹425 Cr	—	A+ (Stable)	Upgraded	ICRA
[ICRA] A () term loans	Term loans	—	₹175 Cr	—	A+ (Stable)	Upgraded	ICRA

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26

Indicative long-term—

Indicative short-term—

Score—

LiquidityStretchedAgency: Adequate

DirectionRating watch – DevelopingAgency outlook: Stable

ICRA rating · Oct 2026A+3 notches below indicative

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

Default	No default on record
Issuer cooperation	Cooperating
Credit enhancement	None – standalone rating
Next action stable or better (model)	21%
Information on file	56% · missing: Annual results history (3+ years), Capex / investment plans, Auditor details, Shareholding pattern

Indicative assessment from public data using the published methodology factors; not a credit rating.

Borrowing & funding lifecycle

⬇ PDF report ⬇ Excel

Can it borrow more?Further funding possible with conditions Next rating action stable or better: 52% (At risk of downgrade) · ML model on 6893 rating histories, AUC 0.653

Rated limits₹600 Cr

Not yet allocated—

Extra debt within 3.5× EBITDA—

Interest coverage3.90×

Limit utilisation—

Open bank charges0 · —

Credit outlook model: 52% chance the next rating action is stable or better
Current rating A+ (investment grade)
Interest coverage 3.9×

Rated limits by facility

Timeline

08 Oct 2026 ICRA upgraded: A+ (Stable)Rated limits ₹600 cr ICRA rationale

08 Oct 2026 Cash & liquid funds ₹275.1 cr, undrawn lines ₹96.2 cr

From the report

Liquidity position: Adequate The liquidity position of SPPL is adequate, supported by a healthy cashflow from operations, cash, cash equivalents and liquid investments of around Rs. 275.1 crore and unutilised working capital limits or around Rs. 96.2 crore as on August 31, 2026.

ICRA rationale

08 Oct 2026 Debt repayments due in FY2027: ₹9.1 cr

From the report

Its cashflows are expected to remain adequate to fund its repayment obligations of around Rs. 9.1 crore in FY2027 and more than Rs. 20.0 crore in FY2028.